Search Results for: EyeYon

EyeYon sees more investment

I reported on Israel’s EyeYon Medical’s contact lens to treat corneal edema in my 11 Aug 2013 newsletter. EyeYon began selling the product this year and has just raised $3.6 million of funds to help recruit staff and develop further … Continue reading

Posted in Israel's Medical Achievements | Leave a comment

Investment in Israeli startups (21/3/21)

Fireblocks raised $133 million; Wiz raised $100 million; Viz.ai raised $71 million; Overwolf raised $52 million; EyeYon Medical raised $25 million; Stor.ai raised $21 million; Vulcan Cyber raised $21 million; Datagen raised $15 million; Ravin raised $15 million; Noogata raised … Continue reading

Posted in Economy & Business | Leave a comment

Breakthrough designation for corneal implant

Israel’s EyeYon Medical (see here) has been awarded Breakthrough Device designation for its EndoArt polymer film implant, attached to the posterior corneal surface, to treat chronic corneal edema. EndoArt has been successful in early human clinical trials. https://eye-yon.com/endoart-received-the-breakthrough-device-designation-from-the-fda/

Posted in Israel's Medical Achievements | Leave a comment

Corneal edema treatment approved for the US

The US FDA has approved the Hyper-CL contact lens for the treatment of corneal edema developed by Israel’s EyeYon Medical. The product is already approved for marketing in Europe. About two million people develop corneal edema annually. http://www.eye-yon.com/press-eyeyon-medical-announces-receiving-fda-510-k-clearance/ https://www.youtube.com/watch?v=rknqew9dhxk  (See … Continue reading

Posted in Israel's Medical Achievements | Leave a comment

Treating corneal edema

(Thanks to Israel21c) Israel’s EyeYon Medical has two solutions for corneal edema, which affects an additional two million patients every year. First, Hyper CL is a patented contact lens that uses osmosis to release fluid build-up. Then a DSPEK polymer … Continue reading

Posted in Israel's Medical Achievements | Leave a comment